Bruker (BRKR) has been on a downward spiral lately with significant selling pressure. After declining 22.5% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is ...

Q1 2024 Earnings Presentation May 2, 2024 BRUKER CORPORATION (NASDAQ: BRKR) Frank H. Laukien, President & Chief Executive Officer Gerald Herman, Executive Vice President & Chief Financial Officer Justin Ward, Senior Director, Investor Relations & Corporate Development Safe Harbor Statement © 2022 Bruker + -Bruker | | Confidential- © 2023 Bruker | | Q1 2024 Business Update Q1 2024 BUSINESS UPDATE Margin Performance Impacted by Tough Comparison, Acquisitions and FX Reconciliations of non-GAAP to GAAP financia ...

Bruker (BRKR) reported $721.7 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 5.3%. EPS of $0.53 for the same period compares to $0.64 a year ago.The reported revenue represents a surprise of -0.30% over the Zacks Consensus Estimate of $723.84 million. With the consensus EPS estimate being $0.46, the EPS surprise was +15.22%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ex ...

Bruker (BRKR) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.64 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15.22%. A quarter ago, it was expected that this scientific equipment maker would post earnings of $0.65 per share when it actually produced earnings of $0.70, delivering a surprise of 7.69%.Over the last four quarters, the ...

Revenue Guidance and Growth - Bruker expects FY 2024 revenues of $3.29 to $3.35 billion, reflecting an increase of $60 million from prior guidance and implying 11% to 13% year-over-year reported revenue growth [17]. - Organic revenue growth for FY 2024 is expected to be 5% to 7%, with constant exchange rate (CER) revenue growth projected at 12% to 14% [17]. - The updated FY 2024 guidance includes contributions from the recently closed acquisitions of Chemspeed and ELITech, but excludes the pending NanoString acquisition [26]. - Updated FY 2024 revenue guidance of $3.29 to $3.35 billion, implying reported growth of 11% to 13% year-over-year [35]. - Revenue for the three months ended March 31, 2024, was $721.7 million, a 5.3% increase from $685.3 million in the same period of 2023 [50]. Quarterly Performance - First quarter 2024 revenues were $721.7 million, a 5.3% increase compared to $685.3 million in Q1 2023, with organic revenue growth of 1.6% year-over-year [24]. - Q1 2024 revenues of $721.7 million, up 5.3% year-over-year; organic revenue up 1.6% year-over-year, and constant-exchange rate (CER) revenue up 5.5% year-over-year [35]. - The Bruker Scientific Instruments (BSI) segment reported revenues of $651.1 million, a 3.9% year-over-year increase, while the Bruker Energy & Supercon Technologies (BEST) segment revenues increased by 17.5% year-over-year to $73.1 million [19]. Earnings and Profitability - Non-GAAP diluted EPS for Q1 2024 was $0.53, down from $0.64 in Q1 2023, while GAAP diluted EPS was $0.35 compared to $0.52 in the prior year [25]. - Non-GAAP operating income for Q1 2024 was $100.7 million, compared to $139.4 million in Q1 2023 [37]. - Non-GAAP operating margin for Q1 2024 was 14.0%, down from 20.3% in Q1 2023 [37]. - FY 2024 non-GAAP EPS guidance raised to $2.79 to $2.84, up $0.08 from prior guidance [39]. - Gross profit for the same period was $352.8 million, down from $359.7 million year-over-year [46]. - Operating income decreased to $64.8 million from $122.7 million in the prior year [50]. - Net income attributable to Bruker Corporation was $50.9 million, compared to $76.5 million in the previous year [50]. - Non-GAAP earnings per share (diluted) for the quarter was $0.53, down from $0.64 in the same quarter last year [46]. - Non-GAAP gross profit was $369.4 million, with a non-GAAP gross margin of 51.2%, compared to 53.4% in the prior year [46]. Expenses and Liabilities - Non-GAAP SG&A expenses for Q1 2024 were $187.1 million, compared to $157.4 million in Q1 2023, reflecting an increase of 18.8% [9]. - Total operating expenses increased to $288.0 million from $237.0 million year-over-year, driven by higher selling, general, and administrative expenses [50]. - Total current liabilities were $1,182.5 million, slightly down from $1,202.1 million [32]. - Total current assets as of March 31, 2024, were $2,140.4 million, a slight decrease from $2,164.2 million as of December 31, 2023 [6]. - Total assets increased to $4,506.4 million as of March 31, 2024, up from $4,249.9 million at the end of 2023 [6]. - Total liabilities, redeemable noncontrolling interests, and shareholders' equity amounted to $4,506.4 million [32]. Cash Flow and Investment Returns - Cash flows from operating activities for Q1 2024 were $21.8 million, down from $87.5 million in Q1 2023 [33]. - Return on invested capital (ROIC) decreased to 17.2% from 24.0% year-over-year [62]. Currency Impact - Foreign currency translation is anticipated to have a negative impact of -1% on revenue, contrasting with a prior expectation of a +1% tailwind [17].

We are in the middle of the first-quarter 2024 earnings season, with numerous MedTech bigwigs having already released first-quarter results. Per the latest Earnings Preview, quarterly results of the Medical sector are projected to decline year over year, affected by the ongoing macroeconomic headwinds, primarily in the form of worldwide geopolitical issues and healthcare labor shortages.Going by the broader Medical sector’s scorecard, 16.7% of the companies in the Medical sector, constituting 32.6% of the s ...

In its upcoming report, Bruker (BRKR) is predicted by Wall Street analysts to post quarterly earnings of $0.46 per share, reflecting a decline of 28.1% compared to the same period last year. Revenues are forecasted to be $723.84 million, representing a year-over-year increase of 5.6%.The consensus EPS estimate for the quarter has been revised 0.7% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during t ...

Bruker Corporation (BRKR) is likely to grow in the coming quarters, backed by the strong potential of the Bruker Scientific Instruments (“BSI”) Nano Group. In BioSpin, strength across end markets, including the new IDS (integrated data solutions) business, sounds encouraging for the company. The CALID Group has also been making decent progress lately, primarily due to the strong demand for differentiated instruments.Meanwhile, exposure to currency fluctuations, as well as competitive challenges, can potenti ...

Bruker (BRKR) continues to grow, banking on its fundamental commitment to innovate high-value solutions and the ongoing portfolio transformation. The stock carries a Zacks Rank #2 (Buy) currently.Bruker’s CALID Group has been making decent progress lately, primarily because of the strong demand for differentiated instruments. The group is benefiting from sustained growth in the mass spectrometry business, including FT-IR, Near IR and Raman molecular spectroscopy product lines. Bruker’s timsTOF platform cont ...

NanoString’s GeoMX Digital Spatial Profiler was at the heart of a patent lawsuit filed by 10x Genomics. (NanoString Image)NanoString announced Wednesday that it will be acquired by Bruker, ending the company’s restructuring process that included a Chapter 11 bankruptcy plan. Bruker, a Massachusetts-based publicly traded life sciences research and diagnostic giant founded in 1960, will pay $392.6 million to buy Seattle-based NanoString. The deal is expected to close next month. NanoString said in February th ...